Pacific Biosciences of California, Inc. (PACB) Posts Q3 EPS Loss of $0.54, Sales Top Expectations

Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q3 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $9.73 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Commercial Metals (CMC) Tops Q3 EPS by 3c, Beats on Revenue
• Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance